Related Experiment Video
Updated: Aug 2, 2026
05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice
A J Mayorga1, A Dalvi, M E Page
1Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6140, USA.
The Journal of Pharmacology and Experimental Therapeutics
|August 16, 2001
Summary
Serotonin receptor knockout mice reveal distinct roles for 5-HT(1A) and 5-HT(1B) receptors in antidepressant drug response. These findings highlight the differential impact of these serotonin receptors on antidepressant efficacy in the tail suspension test.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Serotonin receptors are crucial targets for antidepressant drugs.
- Understanding the specific roles of serotonin receptor subtypes, like 5-HT(1A) and 5-HT(1B), is vital for developing more effective treatments.
- Knockout mouse models offer a unique approach to dissecting receptor function in vivo.
Purpose of the Study:
- To investigate the differential effects of selective serotonin reuptake inhibitors (SSRIs) and a selective norepinephrine reuptake inhibitor (SNRI) on immobility in 5-HT(1A) and 5-HT(1B) receptor knockout mice.
- To elucidate the specific contributions of 5-HT(1A) and 5-HT(1B) receptors to antidepressant drug action using the tail suspension test (TST).
Main Methods:
- Utilized 5-hydroxytryptamine (5-HT)(1A) and 5-HT(1B) receptor knockout mice and wild-type littermates.
- Administered fluoxetine, paroxetine (SSRIs), and desipramine (SNRI) and assessed immobility in the tail suspension test (TST).
- Investigated baseline immobility and drug-induced behavioral changes, and used receptor antagonists in wild-type mice.
Main Results:
- 5-HT(1A) receptor mutant mice exhibited reduced baseline immobility, suggesting a role in modulating depressive-like behavior.
- Desipramine reduced immobility in both wild-type and 5-HT(1A) mutant mice, while fluoxetine and paroxetine were ineffective in 5-HT(1A) mutants.
- Fluoxetine's antidepressant effect was augmented in 5-HT(1B) receptor mutant mice, indicating a differential modulatory role for this receptor.
- Selective 5-HT receptor antagonists partially mimicked the knockout phenotypes in wild-type mice.
Conclusions:
- 5-HT(1A) and 5-HT(1B) receptors play distinct and opposing roles in mediating the behavioral effects of different classes of antidepressant drugs.
- These findings underscore the complexity of serotonin receptor involvement in antidepressant action and suggest subtype-specific therapeutic strategies.
Related Concept Videos
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...